The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity
Completed
Mallinckrodt
Phase 1
2004-07-01
The purpose of this research study is to evaluate MR imaging in subjects receiving
doxorubicin chemotherapy to see if MR can detect heart damage as well as or better than MUGA
scans.
This research study is expected to enroll approximately 10 subjects over 12 months at the
University of Miami / Miller School of Medicine.
The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity
Completed
University of Miami
Phase 1
2004-07-01
The purpose of this research study is to evaluate MR imaging in subjects receiving
doxorubicin chemotherapy to see if MR can detect heart damage as well as or better than MUGA
scans.
This research study is expected to enroll approximately 10 subjects over 12 months at the
University of Miami / Miller School of Medicine.
Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
Completed
Bayer
Phase 2
2005-08-01
The purpose of this study is to look at the safety (what are the side effects) and efficacy
(how well does it work) of Gadavist when used for taking images of the brain and spine. The
results of the MRI with Gadavist Injection will be compared to the results of MR images taken
without contrast and with the results of the MR images taken with OptiMARK.
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients
Completed
Guerbet
Phase 4
2002-05-01
The objective of this study is to characterize the safety, efficacy and pharmacokinetic
profiles of Optimark at the standard clinical dose of 0.1 mmol/kg in the pediatric patient
population.
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients
Completed
Mallinckrodt
Phase 4
2002-05-01
The objective of this study is to characterize the safety, efficacy and pharmacokinetic
profiles of Optimark at the standard clinical dose of 0.1 mmol/kg in the pediatric patient
population.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
